Zenas BioPharma (ZBIO) · obexelimab
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: mid-2026
We expect to complete enrollment in the SunStone trial by year-end 2025 and to report topline results from the SunStone trial in mid-2026.
· filed · SEC filing
After
Stated timing: fourth quarter of 2026
We expect to report data on the primary endpoint at 24 weeks and biomarker data in the fourth quarter of 2026.
· filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/ZBIO-obexelimab-2026-03-16, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/ZBIO-obexelimab-2026-03-16
Zenas BioPharma (ZBIO) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.A Form 10-K is a company’s annual report to the SEC, with audited financial statements.